Merck Strengthens Immunology Pipeline With Acquisition of Prometheus Biosciences, Inc.

Merck, known as MSD outside of the United States and Canada, and Prometheus Biosciences, Inc. announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion. Read more.